Skip to main content
Elsevier

Cancer Immunotherapy

Immune Suppression and Tumor Growth

There has been major growth in understanding immune suppression mechanisms and its relationship to cancer progression and therapy. This book highlights emerging new principles of… Read more

Description

There has been major growth in understanding immune suppression mechanisms and its relationship to cancer progression and therapy. This book highlights emerging new principles of immune suppression that drive cancer and it offers radically new ideas about how therapy can be improved by attacking these principles. Following work that firmly establishes immune escape as an essential trait of cancer, recent studies have now defined specific mechanisms of tumoral immune suppression. It also demonstrates how attacking tumors with molecular targeted therapeutics or traditional chemotherapeutic drugs can produce potent anti-tumor effects in preclinical models. This book provides basic, translational, and clinical cancer researchers an indispensable overview of immune escape as a critical trait in cancer and how applying specific combinations of immunotherapy and chemotherapy to attack this trait may radically improve the treatment of advanced disease.

Key features

* Offers a synthesis of concepts that are useful to cancer immunologists and pharmacologists, who tend to work in disparate fields with little cross-communication
* Drs Prendergast and Jaffee are internationally recognized leaders in cancer biology and immunology who have created a unique synthesis of fundamental and applied concepts in this important new area of cancer research
* Summarizes the latest insights into how immune escape defines an essential trait of cancer
* Includes numerous illustrations including: how molecular-targeted therapeutic drugs or traditional chemotherapy can be combined with immunotherapy to improve anti-tumor efficacy; and how reversing immune suppression by the tumor can cause tumor regression

Readership

Basic, translational, and clinical cancer researchers as well as practicing oncologists and their patients

Table of contents

Part I: Principles of Cancer Immunobiology
Introduction
Cancer Immunoediting: From Immune Surveillance to Immune Escape
Immunosurveillance: Innate and Adaptive Anti-Tumor Immunity
Cytokine Regulation of Immune Tolerance to Tumors
Immunological Sculpting: Natural Killer Cell Receptors and Ligands
Immune Escape: Immunosuppressive Networks
Part II: Cancer Therapeutics
Cytotoxic Chemotherapy in Clinical Treatment of Cancer
Targeted Therapeutics in Cancer Treatment
Concepts in Pharmacology and Toxicology
Cancer Immunotherapy: Challenges and Opportunities
Cancer Vaccines
Part III: Targets and Tactics to Improve Cancer Immunotherapy By Defeating Immune Suppression
Immunotherapy and Cancer Therapeutics: Why Partner?
Immune Stimulatory Features of Classical Chemotherapy
Dendritic Cells and Co-Inhibitory Molecules
Regulatory T Cells in Tumor Immunity: Role of Toll-like Receptors
Tumor-associated Macrophages in Cancer Growth and Progression
Tumor-associated Myeloid-derived Suppressor Cells
Programmed Death Ligand-1 and Galectin-1: Pieces in the Puzzle of Tumor Immune Escape
IDO in Immune Escape: Regulation and Therapeutic Inhibition
Arginase, Nitric Oxide Synthase, and Novel Inhibitors of L-arginine Metabolism in Immune Modulation
Summary: Future Questions

Review quotes

"This relatively compact book is a summary of contemporary thinking about cancer immunotherapy, with a focus on the relationship between tumors and the immune response of the host. The book is edited by authorities on tumor biology and cancer immunotherapy and reflects the nascent synthesis of these disciplines. The chapters are written by highly respected investigators, and the topics span much of the breadth and depth of this evolving field. The book seems designed to provide an overview for those who wish to immerse themselves in this field and who have a working knowledge of immunotherapy but rudimentary familiarity with cancer immunobiology and therapy."—The New England Journal of Medicine, April 2008

Product details

About the editors

GP

George C. Prendergast

Dr. Prendergast is an international leader in basic and preclinical biomedical research, with deep expertise in the discovery and development of molecular therapies for cancer and other chronic diseases. A scientist and inventor, he is widely recognized for translating laboratory discoveries into practical medical innovations and for founding and advising multiple biomedical startup companies. He has led major advances in cancer immunotherapy, including pioneering work on IDO inhibition and the development of cryoimmune vaccination strategies to address drug‑resistant metastatic disease. Formerly Editor‑in‑Chief of Cancer Research, he has played a significant role in shaping the field’s scientific direction. As President and CEO of LIMR, Dr. Prendergast established the acapreneurial™ model, integrating nonprofit research with entrepreneurial biotechnologies to accelerate clinical impact, societal benefit, and sustainable innovation.
Affiliations and expertise
Lankenau Institute for Medical Research, Wynnewood, PA, U.S.A.

EJ

Elizabeth M. Jaffee

Affiliations and expertise
Department of Oncology, SKCCC, Johns Hopkins University, Baltimore, MD, U.S.A.

View book on ScienceDirect

Read Cancer Immunotherapy on ScienceDirect